Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal logo Université Clermont Auvergne & associés

Human Nutrition Unit

Zone de texte éditable et éditée et rééditée

Fragi-Biote

Fragi-Biote
.

Development of a rodent model with an aged human microbiota to test individualized interventional strategies during aging.

Dominique Dardevet  Isabelle Savary-Auzeloux  (Team Improving)

Partners: Jean-Marc Chatel, Claire Cherbuy ( Micalis, jouy en josas), Mathieu Almeida (-Metagenopolis)  

The population aged 60 and over has doubled since 1980 and is expected to reach two billion by 2050. This growth is noticeable not only in developed countries but also in emerging countries. Unfortunately, this increase in longevity does not necessarily mean so-called "successful aging" and there is currently an explosion of chronic noncommunicable diseases (cardiovascular diseases, diabetes, chronic inflammation, cancer ...) which will represent the main causes of co-infection. morbidity, morbidity and mortality in the next few years among the elderly. As a result, the lengthening of this lifespan may be associated with an impaired quality of life, frailty, dependency, and the institutionalization of seniors with an ever increasing public health cost.

Studies in humans have shown that the composition and functions of the gut microbiota play a central role in many pathologies. These evolve with old age. These changes of intestinal microbiota or dysbiosis appear all the more marked that the subjects are in a fragile state of health. Studies show a strong correlation in the elderly between health status and microbiota profile.

Recently, studies of murine microbiota transfer in rodent models have clearly identified that these age-related dysbiosis may play a decisive role in age-related pathologies or complications: thus, it has been shown that the transfer of a microbiota from elderly mice to axenic mice is accompanied, in recipient mice, by changes mimicking characteristics of an elderly organism: increased intestinal permeability, establishment of systemic inflammation and dysfunction of immune cells.

Many nutritional or pharmacological strategies are encouraged to fight or slow down the physiological decline in the broad sense of age. Because of these alterations observed at the level of the microbiota, innovative strategies taking into account the microbiota must now be considered. To achieve effective selection of strategies targeting older people, the use of experimental models is central. The mouse or the rat are the main pre-clinical models, but the microbiota of rodents is very different from that of humans. In order to overcome this problem, our project consists of developing and validating a mouse model of a human microbiota rodent, thus allowing this primordial factor to be taken into account. We will implant a microbiota of healthy or frail elderly people into rodents without germs. We will compare the effect of this transplantation on the physiology of the host with mice in which we have implanted a healthy adult microbiota. Then we will test the "fragility" introduced by the human microbiota of elderly people by an infectious challenge. We will develop a preclinical model that is useful to both the scientific community and industrial partners between the conventional flora rodent model and the human clinical trial.